Enterprise Value (EV)
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Analysis of Liquidity Ratios
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Current Ratio since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Current Enterprise Value (EV)
Vertex Pharmaceuticals Inc., current enterprise value calculation
| Current share price (P) | |
| No. shares of common stock outstanding | |
| US$ in thousands | |
| Common equity (market value)1 | |
| Add: Preferred stock, $0.01 par value; none issued and outstanding (per books) | |
| Total equity | |
| Add: Current finance lease liabilities (per books) | |
| Add: Long-term finance lease liabilities (per books) | |
| Total equity and debt | |
| Less: Cash and cash equivalents | |
| Less: Marketable securities | |
| Enterprise value (EV) | |
Based on: 10-K (reporting date: 2025-12-31).
1 Common equity (market value) = Share price × No. shares of common stock outstanding
= ×
Historical Enterprise Value (EV)
Vertex Pharmaceuticals Inc., EV calculation
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Data adjusted for splits and stock dividends.
2 Closing price as at the filing date of Vertex Pharmaceuticals Inc. Annual Report.
3 2025 Calculation
Common equity (market value) = Share price × No. shares of common stock outstanding
= ×
The information presents a five-year trend of several financial metrics, including common equity market value, total equity, total equity and debt, and enterprise value. A consistent upward trend is observed across all reported items from 2021 through 2025. However, the rate of increase varies between the metrics.
- Common Equity (Market Value) & Total Equity
- Common equity (market value) and total equity exhibit identical values across all reported periods, indicating that market valuation fully reflects the book value of equity. Both metrics demonstrate substantial growth, increasing from approximately US$62.2 billion in 2021 to US$124.9 billion in 2025. The growth rate appears to accelerate between 2021 and 2023, then moderates slightly in the subsequent two years.
- Total Equity and Debt
- Total equity and debt also shows a consistent increase, rising from US$62.7 billion in 2021 to US$125.0 billion in 2025. The magnitude of the increase is relatively consistent year-over-year, suggesting a stable capital structure policy. The difference between total equity and debt remains relatively small throughout the period.
- Enterprise Value (EV)
- Enterprise value demonstrates a similar upward trajectory, growing from US$55.2 billion in 2021 to US$118.4 billion in 2025. While generally aligned with the growth in equity and debt, the rate of EV increase is slightly lower than that of common equity and total equity, particularly in 2022 and 2023. This suggests potential changes in the company’s cash position or other non-equity factors influencing valuation. The growth rate of EV also moderates in 2024 and 2025, mirroring the trend observed in equity metrics.
Overall, the financial metrics indicate a period of sustained growth. The consistent increases in equity, debt, and enterprise value suggest positive business performance and investor confidence. The slight divergence in growth rates between EV and equity warrants further investigation to understand the underlying drivers.